Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Staar Surgical (STAA)
NASDAQ:STAA
Earnings Data
Report Date
Apr 30, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.57Last Year’s EPS
0.11Same Quarter Last Year
Based on 9 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 11, 2025
|% Change Since: -22.99%
|Next Earnings Date:Apr 30, 2025
Earnings Call Sentiment|Negative
STAAR Surgical faced significant challenges in China, which overshadowed strong performance in other regions. While the company continues to grow outside of China and gain market share in the U.S., the decline in China sales and the unrecognized revenue due to extended payment terms have negatively impacted overall results. The company remains optimistic about future growth and recovery, particularly in China, but the current challenges have led to a cautious outlook for fiscal 2025.Company Guidance
In the STAAR Surgical Q4 2024 earnings call, guidance for fiscal 2025 was discussed with several metrics highlighted. The company anticipates ICL sales outside China to range from $165 million to $175 million, reflecting a growth of 9% to 15%. In China, due to elevated inventory levels and economic uncertainty, ICL sales are projected between $75 million and $125 million. This wide range accounts for potential fluctuations in the refractive market, with a decline of up to 10% or a rebound of up to 10%. The total net sales for fiscal 2024 were $313.9 million, a 3% decline from 2023, largely due to a significant drop in China sales, including an unrecognized $27.5 million shipment. Despite this, sales outside China saw a resilient growth, with the Americas achieving a 22% increase in Q4 and 15% for the year. The guidance also considers macroeconomic conditions, especially in China, where consumer confidence and retail dynamics remain volatile, impacting the demand for ICLs. Adjusted EBITDA loss for 2025 is projected between $50 million to $15 million, with cash reserves expected to end between $150 million to $175 million.Strong Growth Outside of China
STAAR generated $152 million of ICL sales outside of China, reflecting growth of 17% in Q4 and 13% for the fiscal year 2024.
U.S. Market Share Gains
In the U.S., STAAR achieved sales growth of 22% in Q4 and 15% for the fiscal year, outperforming a market that saw a decline in laser vision correction procedures.
Diverse Global Presence
STAAR's business is geographically diverse, with sales in over 75 countries, demonstrating strong performance in regions like EMEA and APAC (excluding China).
---
STAA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
STAA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 11, 2025 | $21.88 | $16.48 | -24.68% |
| Oct 30, 2024 | $29.49 | $28.99 | -1.70% |
| Aug 07, 2024 | $36.35 | $40.36 | +11.03% |
| May 07, 2024 | $46.65 | $41.02 | -12.07% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Staar Surgical (STAA) report earnings?
Staar Surgical (STAA) is schdueled to report earning on Apr 30, 2025, TBA Not Confirmed.
What is Staar Surgical (STAA) earnings time?
Staar Surgical (STAA) earnings time is at Apr 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is STAA EPS forecast?
STAA EPS forecast for the fiscal quarter 2025 (Q1) is -0.57.
---